Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to $71.0 million.

  • Myriad Genetics' Other Operating Expenses fell 152.57% to $71.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $622.5 million, marking a year-over-year increase of 8228.4%. This contributed to the annual value of $319.6 million for FY2024, which is 2049.75% down from last year.
  • Latest data reveals that Myriad Genetics reported Other Operating Expenses of $71.0 million as of Q3 2025, which was down 152.57% from $388.6 million recorded in Q2 2025.
  • Myriad Genetics' 5-year Other Operating Expenses high stood at $388.6 million for Q2 2025, and its period low was $47.8 million during Q3 2021.
  • For the 5-year period, Myriad Genetics' Other Operating Expenses averaged around $94.5 million, with its median value being $71.0 million (2025).
  • In the last 5 years, Myriad Genetics' Other Operating Expenses tumbled by 3762.01% in 2024 and then soared by 36042.65% in 2025.
  • Myriad Genetics' Other Operating Expenses (Quarter) stood at $107.8 million in 2021, then grew by 15.86% to $124.9 million in 2022, then dropped by 7.45% to $115.6 million in 2023, then decreased by 18.94% to $93.7 million in 2024, then dropped by 24.23% to $71.0 million in 2025.
  • Its Other Operating Expenses was $71.0 million in Q3 2025, compared to $388.6 million in Q2 2025 and $69.2 million in Q1 2025.